Impact of New Antifungal Breakpoints on Antifungal Resistance in Candida Species
Open accessAbstract
We reviewed our antifungal susceptibility data for micafungin, anidulafungin, fluconazole, and voriconazole against Candida species and compared resistance rates determined by the previous and recently revised CLSI antifungal breakpoints. With the new breakpoints, resistance was significantly increased for micafungin (from 0.8% to 7.6%), anidulafungin (from 0.9% to 7.3%), and voriconazole (from 6.1% to 18.4%) against Candida glabrata . Resistance was also increased for fluconazole against Candida albicans (from 2.1% to 5.7%).
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The pitavastatin-fluconazole interactions were not sufficient to restore fluconazole activity in several fluconazole-resistant isolates; two C. albicans and four C. auris isolates maintained their resistance profiles to fluconazole.
“Of note, although pitavastatin was able to demonstrate broad-spectrum synergistic interactions with fluconazole, these interactions were not sufficient to restore the antifungal activity of fluconazole in several fluconazole-resistant isolates. Considering the current resistance breakpoints for azole drugs, two C. albicans and four C. auris isolates maintained their resistance profiles to fluconaz”
From Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant Candida species (2020) · cites this paper as [36]
The citation lists haven’t been fetched yet
References 17 · Cited by 96
- Authors
- Fothergill, A. W., Sutton, D. A., McCarthy, D. I., & Wiederhold, N. P.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2014-03
- Volume
- 52
- Issue
- 3
- Pages
- 994-997
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC3957792
- OpenAlex
- W1969488802
- Cited by
- 96
- References
- 17
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 4 · 2023: 6 · 2022: 3 · 2021: 8 · 2020: 8 · 2019: 12 · 2018: 17 · 2017: 12 · 2016: 7 · 2015: 6 · 2014: 5
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Antibiotic Resistance in Bacteria
- Keywords
- antifungal resistance, Candida, micafungin, anidulafungin, fluconazole, voriconazole, Candida glabrata, Candida albicans, CLSI guidelines, antifungal susceptibility
- MeSH terms
- Antifungal Agents, Candida, Candidiasis, Humans, Microbial Sensitivity Tests, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
